A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 4
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 274
- Population
- ALL · 50 Years
- Duration
- 2025-03-14 to 2027-09-20
- Intervention
- Faricimab
- Comparator
- Not reported
- Outcomes measured
- Change from Baseline in Best-Corrected Visual Acuity (BCVA) Score Averaged Over Weeks 44, 48, and 52 — Baseline and ave…; Change from Baseline in BCVA Score Averaged Over Weeks 92, 96, and 100 — Baseline and average of Weeks 92, 96, and 100; Change from Baseline in BCVA Score Over Time — From Baseline to Week 100; Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA from Baseline Over Time — From Baseline to Week 100; Percentage of Participants with BCVA Snellen Equivalent of 20/40 or Better Over Time — From Baseline to Week 100; Percentage of Participants with BCVA Snellen Equivalent of 20/200 or Worse Over Time — From Baseline to Week 100; Change from Baseline in Central Subfield Thickness (CST) Averaged Over Weeks 44, 48, and 52 — Baseline and average of W…; Change from Baseline in CST Averaged Over Weeks 92, 96, and 100 — Baseline and average of Weeks 92, 96, and 100; Change from Baseline in CST Over Time — From Baseline to Week 100; Percentage of Participants on Different Treatment Intervals at Weeks 52 and 100 — Weeks 52 and 100; Incidence and Severity of Ocular Adverse Events — From first study treatment to Week 100; Incidence and Severity of Non-Ocular Adverse Events — From first study treatment to Week 100
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.